340 related articles for article (PubMed ID: 21220502)
1. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP; Premkumar DR; Pollack IF
Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
[TBL] [Abstract][Full Text] [Related]
3. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
10. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma.
Hetschko H; Voss V; Horn S; Seifert V; Prehn JH; Kögel D
J Neurooncol; 2008 Feb; 86(3):265-72. PubMed ID: 17924059
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
18. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
